New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

49

Pfizer’s Braftovi to command 42% share of BRAF inhibitors melanoma market by 2028

Since Roche’s Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma. Against this backdrop, Pfizer’s Braftovi (encorafenib) is positioned to secure a dominant 42% share of the BRAF inhibitors market for melanoma by 2028, underscoring its pivotal role in cancer therapy.